Recently, Curant COO Marc O’Connor spoke with Renay San Miguel from Georgia Public Broadcasting on the Curant’s prescription for growth. In addition to its superior patient care model, with an established 98% retention rate, Curant’s financial success has caught the attention of industry leaders. Since its inception in 2000, Curant has been recognized by industry […]
July 30, 2015 - Curant Health President and CEO, Patrick Dunham, in MedCity News - In my role as CEO of one of the nation’s largest independent 340B specialty pharmacies, I found the past six months leading up to the 340B Coalition Summer 2015 Conference were much quieter than in the past. Is the healthcare […]
Presenting with a CD4 count of only 21, doctors gave Robert W. mere months to live. Weighing only 98 pounds, his HIV had progressed to Stage 3 AIDS, and he was on his deathbed. Robert had been prescribed seven different HIV medications and had a long history of struggling with his HIV treatment compliance due […]
The writing has been on the wall from some time. The push for value-based care has had a domino effect on biopharmaceutical manufacturers. The new industry trend will be for them to go “at-risk” in negotiations with payers and PBMs for new high-cost specialty therapies. Factors that increase the need for biopharma manufacturers to go […]
November 17, 2015 - Curant COO, Marc O'Connor, in Specialty Pharmacy Times - During a strategy session in June, my colleagues at Curant Health and I identified the need for biopharmaceutical manufacturers to go “at risk” in negotiations with payers and PBMs for new high cost specialty therapies as a near-term industry trend. “At risk” […]
What are the new questions regarding HIV treatment? When it comes to hepatitis C, Gilead drugs Harvoni and Sovaldi have validated their value-based care. If faced with the options of spending $577,000 on a liver transplant or $94,500 on a course of Harvoni for hepatitis C, it’s a no brainer which option is more favorable. […]
For employees at Curant Health, caring for patients is a fundamental job role. Advocating on behalf of our patients, verifying and collaborating with insurance payors to ensure accurate flow of information and medication coverage are all daily responsibilities that require a high degree of care and compassion. At Curant Health, we witness our employees dutifully […]
ACG 2015 was a remarkable mixture of clinicians, manufacturers and medical device companies focused on the sharing the new processes, drugs and technology targeted to the gastroenterology space. In addition to IBD-related topics, hepatitis c and new medication therapies were the topic of much discussion. As expected, clinicians provided most of this year’s most valuable conference […]
November 3, 2015 – Curant HCV program director, Amy Hampton, in Managed Healthcare Executive – In August, Bloomberg reported that Gilead, “...is setting ambitious goals to vanquish two major viral scourges: HIV and hepatitis B. The biotech company dominates the HIV market, estimating that about 80% of new patients starting therapy are prescribed a Gilead […]
October 20, 2015 - Curant COO, Marc O'Connor, in MedCity News - Biopharmaceutical manufacturers have been taking it on the chin lately as prices continue to skyrocket. The battery continues as candidates vying for their respective party’s nomination for the 2016 presidential campaign take their positions. As Chris Seper reported via Matthew Herper at Forbes, […]
